2025
Industrial Air Emissions and Breast Cancer Incidence in a United States-wide Prospective Cohort
Ish J, Madrigal J, Pearce J, Keil A, Fisher J, Jones R, Sandler D, White A. Industrial Air Emissions and Breast Cancer Incidence in a United States-wide Prospective Cohort. Epidemiology 2025, 36: 391-400. PMID: 39855262, DOI: 10.1097/ede.0000000000001837.Peer-Reviewed Original ResearchBreast cancer incidenceCancer incidenceBreast cancerIncidence of breast cancerEstimate adjusted hazard ratiosHazard ratioAssociated with breast cancerIncident breast cancerConfidence intervalsBreast cancer casesAdjusted hazard ratiosCox proportional hazards regressionProportional hazards regressionParticipating residentsCancer casesHazards regressionProspective cohortStudy enrollmentElevated associationIndustrial air emissionsIndustrial carcinogensCharacterized associationsBreastFollow-upPollutant mixtures
2024
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 209: 21-26. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.Peer-Reviewed Original ResearchHigh-risk family historyFamily historyRare germline variantsCancer riskSNP-set kernel association testAssociated with breast cancer riskCancer casesContribution of family historyEarly-onset breast cancerCancer prevention clinicBreast cancerBreast cancer riskKernel association testBreast cancer casesCancer-predisposing genesGermline variantsGermline pathogenic variantsYoung womenPrevention clinicSKAT-OBurden testsPathogenic variantsExome sequencing dataAssociation TestLevel alterationsComparison of incident breast cancer cases in the largest national US tumor registries
Plichta J, Thomas S, Chanenchuk T, Chan K, Hyslop T, Hwang E, Greenup R. Comparison of incident breast cancer cases in the largest national US tumor registries. Cancer 2024, 131: e35525. PMID: 39154223, PMCID: PMC11695170, DOI: 10.1002/cncr.35525.Peer-Reviewed Original ResearchIncident breast cancer casesUS Cancer StatisticsBreast cancer casesNational Cancer DatabaseNon-HispanicNon-Hispanic American Indian/Alaska NativesCancer casesTumor RegistryIn situ breast cancerPopulation cancer registryNon-Hispanic blacksSamples of breast cancer patientsNon-Hispanic whitesAmerican Indian/Alaska NativeEnd Results ProgramBreast cancerPacific IslandersCancer RegistryCancer statisticsIndian/Alaska NativeCase ascertainmentInterpretation of findingsResults ProgramBreast cancer patientsRegistryQuantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay
Liu M, Vathiotis I, Robbins C, Chan N, Moutafi M, Burela S, Xirou V, Schalper K, Herbst R, Syrigos K, Rimm D. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology 2024, 37: 100556. PMID: 38964502, PMCID: PMC11416319, DOI: 10.1016/j.modpat.2024.100556.Peer-Reviewed Original ResearchNon-small cell lung cancerCases of non-small cell lung cancerNon-small cell lung cancer casesT-DXdCell lung cancerHER2 expressionBreast cancerRare case of non-small cell lung cancerQuantitative immunofluorescenceAntibody-drug conjugate trastuzumab deruxtecanLung cancerHER2 antibody-drug conjugatesNon-small cell lung cancer patientsDetecting HER2 expressionHER2-Targeted TherapyMetastatic breast cancerHER2 protein expressionBreast cancer casesHER2 protein levelsAntibody-drug conjugatesProportion of casesTrastuzumab deruxtecanNSCLC casesFrequency of casesImmunohistochemistry scoreExposure to per- and polyfluoroalkyl substances and breast cancer risk: a systematic review and meta-analysis of epidemiologic studies
Chang C, Ish J, Chang V, Daniel M, Jones R, White A. Exposure to per- and polyfluoroalkyl substances and breast cancer risk: a systematic review and meta-analysis of epidemiologic studies. American Journal Of Epidemiology 2024, 193: 1182-1196. PMID: 38400646, PMCID: PMC11299034, DOI: 10.1093/aje/kwae010.Peer-Reviewed Original ResearchBreast cancer riskCancer riskOverall breast cancer riskMeta-analysis of epidemiological studiesPostmenopausal breast cancer casesSystematic reviewEpidemiological evidenceRandom-effects meta-analysesBreast cancer casesMeta-analysisBreast cancer diagnosisCancer casesCancer diagnosisStudy designMeta-analysesExposure measurementsExposure to per-Epidemiological studiesPositive associationHeterogeneous associationsAssess exposureBreast cancerProgesterone receptor statusEvaluation toolPolyfluoroalkyl substances exposuresBreast cancer incidence trends in Golestan, Iran: An age-period-cohort analysis by ethnic region, 2004-2018
Ghasemi-Kebria F, Fazel A, Semnani S, Etemadi A, Naeimi-Tabiei M, Hasanpour-Heidari S, Salamat F, Jafari-Delouie N, Sedaghat S, Sadeghzadeh H, Akbari M, Mehrjerdian M, Weiderpass E, Roshandel G, Bray F, Malekzadeh R. Breast cancer incidence trends in Golestan, Iran: An age-period-cohort analysis by ethnic region, 2004-2018. Cancer Epidemiology 2024, 89: 102525. PMID: 38228040, DOI: 10.1016/j.canep.2024.102525.Peer-Reviewed Original ResearchAge-standardized incidence rateAge-period-cohortIncidence rate ratiosAge-period-cohort analysisIncidence trendsCalculated age-standardized incidence ratesBreast cancer incidence trendsTrends of breast cancerCohort effectsNon-linear cohort effectsIncidence rateFemale breast cancer casesCancer incidence trendsBreast cancer incidenceAnnual percentage changeIncreased IRRsRural areasBreast cancer casesBreast cancerCancer incidenceDiagnosis yearReproductive factorsBirth cohortCancer casesRate ratios
2023
Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.Peer-Reviewed Original ResearchComprehensive genomic profilingBreast cancerYoung womenGenomic alterationsAdvanced breast cancerPD-L1 expressionTargetable genomic alterationsWorse clinical outcomesTime of diagnosisTumor mutational burdenCross-sectional studyBreast cancer casesFoundation MedicineClinical outcomesPIK3CA mutationsCancer casesEstrogen receptorMutational burdenOlder womenConclusionOur findingsTotal casesBreast tumorsTumor tissueBRCA1 mutationsMicrosatellite instabilityResidential Proximity to Carcinogenic Industrial Air Emissions and Breast Cancer Incidence in a United States-Wide Prospective Cohort
Ish J, Madrigal J, Pearce J, Keil A, Fisher J, Jones R, White A. Residential Proximity to Carcinogenic Industrial Air Emissions and Breast Cancer Incidence in a United States-Wide Prospective Cohort. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 865-865. DOI: 10.1158/1055-9965.epi-23-0376.Peer-Reviewed Original ResearchBreast cancer incidenceIncident breast cancerCancer incidenceHazard ratioParticipating residentsAssociated with breast cancer incidenceBreast cancerEstimate adjusted hazard ratiosAssociated with breast cancerConfidence intervalsBreast cancer casesIndustrial carcinogensAdjusted hazard ratiosCox proportional hazards regressionExposure-response functionsProportional hazards regressionBaseline residenceExposure prevalenceCancer casesResidential proximityHazards regressionProspective cohortIndustrial air emissionsParticipantsResidentsComparison of incident breast cancer cases in the largest national US tumor registries.
Plichta J, Thomas S, Record S, Hyslop T, Hwang E, Greenup R. Comparison of incident breast cancer cases in the largest national US tumor registries. Journal Of Clinical Oncology 2023, 41: 6512-6512. DOI: 10.1200/jco.2023.41.16_suppl.6512.Peer-Reviewed Original ResearchIncident breast cancer casesNumber of patientsRace/ethnicityBreast cancer casesTumor RegistryCase ascertainmentBreast cancerCancer casesPatient countsNon-Hispanic American Indian/Alaska NativesNational tumor registryYear of diagnosisMale breast cancerPopulation cancer registryBreast cancer patientsPacific Islander patientsAmerican Indians/Alaska NativesNon-Hispanic blacksNon-Hispanic whitesChi-square testPublic-use databaseFemale patientsHispanic patientsTreatment patternsCancer RegistryDisparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategies
2022
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
Moutafi M, Robbins C, Yaghoobi V, Fernandez A, Martinez-Morilla S, Xirou V, Bai Y, Song Y, Gaule P, Krueger J, Bloom K, Hill S, Liebler D, Fulton R, Rimm D. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Laboratory Investigation 2022, 102: 1101-1108. PMID: 36775350, DOI: 10.1038/s41374-022-00804-9.Peer-Reviewed Original ResearchConceptsHER2 expressionBreast cancerAttomol/HER2 proteinBreast cancer patientsBreast cancer casesOptimal patient careLevels of HER2Trastuzumab deruxtecanT-DXdCancer patientsLow HER2Cancer casesConventional assaysHER2Patient careAntibody concentrationsQuantitative immunofluorescenceAntibody drugsCancerCell linesAssaysExpressionHER2 detectionLower rangeEvaluating information loss in the National Cancer Database from cases lost to follow‐up
Cotler JH, Nogueira L, McCabe R, Nelson H, Brajcich BC, Boffa DJ, Lum SS, Harris JB, Hawhee V, Mullett TW, Bilimoria KY, Palis BE. Evaluating information loss in the National Cancer Database from cases lost to follow‐up. Journal Of Surgical Oncology 2022, 126: 1123-1132. PMID: 36029288, DOI: 10.1002/jso.26977.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer casesPediatric casesAdult casesCancer DatabaseRectal cancer casesLung cancer casesMean survival timeBreast cancer casesHazard ratioCancer RegistryYears postdiagnosisSurvival outcomesLymphoma casesSurvival timeLeukemia casesSurvival analysisResource burdenFollowTotalMinimal differencesYearsAnnual increasePostdiagnosisPatients
2021
On cross-ancestry cancer polygenic risk scores
Fritsche L, Ma Y, Zhang D, Salvatore M, Lee S, Zhou X, Mukherjee B. On cross-ancestry cancer polygenic risk scores. PLOS Genetics 2021, 17: e1009670. PMID: 34529658, PMCID: PMC8445431, DOI: 10.1371/journal.pgen.1009670.Peer-Reviewed Original ResearchConceptsPolygenic risk scoresGenome-wide association studiesProstate cancer polygenic risk scoresPolygenic risk score distributionRecruitment of diverse participantsAncestry groupsPolygenic risk score methodsRisk scoreNon-genetic risk factorsElectronic health recordsBreast cancer casesHealth recordsUK BiobankGWAS effortsDisease risk assessmentCancer casesAssociation studiesGenetic dataEuropean ancestryPersonalized risk stratificationSummary statisticsRisk factorsAncestryDiverse participantsField of cancerCost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rate
2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor sizeDioxin exposure and breast cancer risk in a prospective cohort study
VoPham T, Bertrand KA, Jones RR, Deziel NC, DuPré NC, James P, Liu Y, Vieira VM, Tamimi RM, Hart JE, Ward MH, Laden F. Dioxin exposure and breast cancer risk in a prospective cohort study. Environmental Research 2020, 186: 109516. PMID: 32305677, PMCID: PMC7363533, DOI: 10.1016/j.envres.2020.109516.Peer-Reviewed Original ResearchConceptsNurses' Health Study IIBreast cancer riskInvasive breast cancer riskHealth Study IICancer riskDioxin exposureHazard ratioBreast cancer risk factorsInvasive breast cancer casesInvasive breast cancer diagnosisER- breast cancerMedical record reviewProspective cohort studyCancer risk factorsConfidence intervalsBreast cancer casesResidential proximityGeocoded residential addressesPositive associationBreast cancer diagnosisBiennial questionnairesCohort studyMenopausal statusRecord reviewRisk factors
2019
Predicting breast cancer risk using personal health data and machine learning models
Stark GF, Hart GR, Nartowt BJ, Deng J. Predicting breast cancer risk using personal health data and machine learning models. PLOS ONE 2019, 14: e0226765. PMID: 31881042, PMCID: PMC6934281, DOI: 10.1371/journal.pone.0226765.Peer-Reviewed Original ResearchConceptsBreast cancer riskBreast cancer risk predictionCancer riskCancer risk predictionGail modelBreast cancer risk prediction toolsCancer risk prediction toolsPositive breast cancer casesHormone replacement therapyRisk stratification toolRisk predictionRisk prediction toolsHealth dataBreast cancer casesPersonal health dataStratification toolReplacement therapyLeading causeBreast cancerCancer casesInvasive proceduresBCRATDeLong testLogistic regressionEarly breast cancer detectionInvestigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.
Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.Peer-Reviewed Original ResearchFemale breast cancer patientsBreast cancer patientsNCCN criteriaCancer patientsGenetic counselingHigher breast cancer mortality ratesYounger ageHBOC testingBreast cancer mortality ratesOvarian cancer syndromeBreast cancer treatmentBreast cancer casesCancer mortality ratesYears of ageTesting servicesFurther genetic counselingPre-test counselingBreast cancer diagnosisNCCN guidelinesChart reviewFemale patientsOncology unitBreast cancerCancer casesFamily history
2018
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL. Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. Npj Breast Cancer 2018, 4: 40. PMID: 30564631, PMCID: PMC6288133, DOI: 10.1038/s41523-018-0095-1.Peer-Reviewed Original ResearchPD-L1 expressionBreast cancer intrinsic subtypesB7-H4Clinico-pathological variablesB7-H4 proteinPD-L1Breast cancerIntrinsic subtypesB7-H4 protein expressionCD28/B7 familyTumor PD-L1 expressionQuantitative immunofluorescenceTriple-negative breast cancerRelationship of tumorCo-inhibitory moleculesImmune checkpoint inhibitorsClinico-pathological characteristicsFraction of patientsNegative breast cancerTissue microarray formatBreast cancer casesPD-L1 proteinCheckpoint inhibitorsClinical benefitExclusive pattern
2016
Breast cancer in systemic lupus
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusBreast cancer riskAnti-dsDNA positivityBreast cancer casesBreast cancerCancer riskDisease activitySLE patientsHazard ratioCancer casesSLE samplesBreast cancer hazard ratioCancer hazard ratioCumulative disease activityFemale SLE patientsCase-cohort analysisCancer-free controlsCohort entrySLE durationClinical characteristicsSystemic lupusClinical factorsLupus erythematosusDrug exposureFamily history
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply